Reneo Pharma appoints Gregory Flesher to its Board as CEO and announces $95m Series B financing co-led by Novo Ventures and Abingworth
– USA, CA – Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases, today announced it raised $95 million in a Series B financing co-led by Novo Ventures and Abingworth and supported by existing investors New Enterprise Associates, RiverVest Venture Partners, Pappas Capital, and Lundbeckfonden Ventures, as well as new investors Rock Springs Capital, Aisling Capital, Amzak Health, and other investors.…